# Phase 2 Leukemia, Myelomonocytic, Chronic trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials in phase 2 for Leukemia, Myelomonocytic, Chronic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Leukemia, Myelomonocytic, Chronic trials: 21 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/leukemia-myelomonocytic-chronic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 13, 2026 | NCT07468916 | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic... | Jonsson Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468916) |
| November 25, 2025 | NCT07249346 | Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249346) |
| July 1, 2025 | NCT07046078 | Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell... | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07046078) |
| June 24, 2025 | NCT07033598 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | Theradex | Phase 2 | Recruiting | Leukemia, Myelomonocytic, Chronic | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07033598) |
| March 28, 2025 | NCT06900088 | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06900088) |
| March 5, 2025 | NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With... | Center for International Blood and Marrow Transplant Research | Phase 2 | Recruiting | AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic... | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859424) |
| February 7, 2025 | NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06815003) |
| January 16, 2025 | NCT06778187 | Oral-ATO for TP53-mutated Myeloid Malignancies | The University of Hong Kong | Phase 2 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, TP53 Gene Mutation, Arsenic Trioxide | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06778187) |
| November 15, 2024 | NCT06691217 | Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis | Massachusetts General Hospital | Phase 2 | Recruiting | Vascular Inflammation, ASCVD, ASCVD Management | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06691217) |
| August 22, 2024 | NCT06566742 | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06566742) |
| April 9, 2024 | NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial | Imperial College London | Phase 2 | Recruiting | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06355583) |
| January 11, 2022 | NCT05184842 | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | Montefiore Medical Center | Phase 2 | Recruiting | Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05184842) |
| August 9, 2021 | NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Cogent Biosciences, Inc. | Phase 2 | Recruiting | Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL)... | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04996875) |
| May 17, 2021 | NCT04888741 | Methods of T Cell Depletion Trial (MoTD) | University of Birmingham | Phase 2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Non... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04888741) |
| January 23, 2020 | NCT04239157 | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent... | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04239157) |
| December 12, 2019 | NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04195633) |
| June 27, 2019 | NCT03999723 | Combining Active and Passive DNA Hypomethylation | Sponsor not shown (see the record) | Phase 2 | Recruiting | Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03999723) |
| September 25, 2018 | NCT03683433 | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03683433) |
| February 1, 2018 | NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | Mayo Clinic | Phase 2 | Recruiting | Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03418038) |
| December 26, 2017 | NCT03383575 | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, IDH2 Gene... | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03383575) |
| April 5, 2016 | NCT02727803 | Personalized NK Cell Therapy in CBT | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02727803) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 5 |
| Fred Hutchinson Cancer Center | 2 |
| Jonsson Comprehensive Cancer Center | 1 |
| The University of Hong Kong | 1 |
| Cogent Biosciences, Inc. | 1 |
| City of Hope Medical Center | 1 |
| University of Birmingham | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| Imperial College London | 1 |
| Massachusetts General Hospital | 1 |
| Mayo Clinic | 1 |
| Theradex | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Montefiore Medical Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| United Kingdom | 4 |
| Hong Kong | 1 |
| Australia | 1 |
| Austria | 1 |
| Belgium | 1 |
| Canada | 1 |
| France | 1 |
| Germany | 1 |
| Italy | 1 |
| Netherlands | 1 |
| Norway | 1 |
| Poland | 1 |
| Spain | 1 |
| Switzerland | 1 |
| Denmark | 1 |
| Sweden | 1 |
| China | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Siding contractors in the United States](https://specstream.ai/data/businesses/siding-contractors/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Import and export companies in the United States](https://specstream.ai/data/businesses/import-and-export-companies/united-states)
- [Elementary schools in the United States](https://specstream.ai/data/businesses/elementary-schools/united-states)
- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
- [Wholesalers in the United States](https://specstream.ai/data/businesses/wholesalers/united-states)
